RESUMO
Volatile oils are important active components in traditional Chinese medicine, but their components are complicated and unstable. It is common to use cyclodextrin inclusion technique to improve the stability of volatile oils and make them easier to be prepared. At present, ß-cyclodextrin (ß-CD) is the most common inclusion material. The evaluation indicators for inclusion technique usually contain the inclusion rate and the oil content in the inclusion compound. However, the articles about the study on selecting inclusion materials for volatile oils were few. In this paper, menthol, the main active ingredient of mint volatile oil, was used as model drug, while ß-CD and hydroxypropyl-ß-cyclodextrin (HP-ß-CD) were used as the inclusion materials. Inclusion equilibrium constant (K), solubilization ratio were investigated, and the results were combined with IR, DSC and TG to verify the formation of inclusion complexes. It turned out that in the range of 0-15 mmolâ¢L⻹, the solubility of menthol was increased linearly with the increase of HP-ß-CD concentration, with AL-type phase solubility diagram, K=3 188.62 Lâ¢mol⻹; in the range of 0-12.5 mmolâ¢L⻹, the solubility of menthol was increased linearly with the increase of ß-CD concentration, K=818.73 Lâ¢mol⻹. When the concentration was over 12.5 mmolâ¢L⻹, the solubility of menthol appeared to be a negative deviation with the increase of ß-CD concentration, with AN-type solubility diagram. The above results showed that the inclusion behavior was different between ß-CD and HP-ß-CD, laying a foundation for further study on inclusion complexes of volatile oil.
Assuntos
2-Hidroxipropil-beta-Ciclodextrina/química , Mentol/química , Óleos Voláteis/química , beta-Ciclodextrinas/química , Medicina Tradicional Chinesa , SolubilidadeRESUMO
OBJECTIVES: This study aimed to investigate the availability, price, and affordability of nationally negotiated innovative anticancer medicines in China. DESIGN: Retrospective observational study based on data from a nationwide medical database. DATA SOURCES/SETTING: Quarterly data about the use of innovative anticancer medicines from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. This study covered 895 public general hospitals in 30 provincial administrative regions in China. Of the total hospitals, 299 (33.41%) were secondary and 596 (66.59%) were tertiary. MAIN OUTCOME MEASURES: The adjusted WHO and Health Action International methodology was used to calculate the availability and affordability of 33 nationally negotiated innovative anticancer medicines in the investigated hospitals. Price is expressed as the defined daily dose cost. RESULTS: On average, the total availability of 33 innovative anticancer medicines increased annually from 2020 to 2022. The median availability of all investigated medicines in tertiary hospitals from 2020 to 2022 was 24.04%, 33.60% and 37.61%, respectively, while the indicators in secondary hospitals were 4.90%, 12.54% and 16.48%, respectively. The adjusted prices of the medicines newly put in Medicare (in March 2021) decreased noticeably, with the decline rate ranging from 39.98% to 82.45% in 2021 compared with those in 2020. Most generic brands were priced much lower than the originator brands. The affordability of anticancer medicines has improved year by year from 2020 to 2022. In comparison, rural residents had lower affordability than urban residents. CONCLUSIONS: The overall accessibility of 33 nationally negotiated innovative anticancer medicines improved from 2020 to 2022. However, the overall availability of most anticancer medicines in China remained at a low level (less than 50%). Further efforts should be made to sufficiently and equally benefit patients with cancer.